An observational cohort study to assess N-acetylglucosamine for COVID-19 treatment in the inpatient setting

CONCLUSIONS: N-acetylglucosamine administration was associated with reduced hospital length-of-stay, ICU admission rates, and death/hospice rates in adults with COVID-19 compared to those who received standard care alone. An upcoming trial will further investigate N-acetylglucosamine's effects.TRIAL REGISTRATION: NCT04706416.PMID:34306677 | PMC:PMC8282940 | DOI:10.1016/j.amsu.2021.102574

Source: Annals of Medicine - July 26, 2021 Category: Internal Medicine Authors: Ameer E Hassan Source Type: research